Fox 5 San Diego

STELARA® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis

As the first and only biologic targeting both cytokines interleukin (IL)-12 and IL-23, STELARA provides a new therapeutic option for children six years of age and older living with active psoriatic ...
FiercePharma

STELARA® Receives CHMP Positive Opinion For Treatment Of Adolescents With Moderate To Severe Psoriasis In Europe

STELARA Recommended for Approval in Paediatric Patients 12 Years and Older with Moderate to Severe Psoriasis Beerse, Belgium, 22 May 2015 - Janssen-Cilag International NV ("Janssen") announced today ...
FierceBiotech

Stelara Shows Greater Efficacy than Etanercept for Treatment Of Moderate-To-Severe Plaque Psoriasis

Toronto, ON, (January 14, 2010) -Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA® (ustekinumab) with Enbrel* (etanercept) in the treatment of ...
Monthly Prescribing Reference

Maintenance Treatment with Stelara Evaluated in Crohn’s Disease Study

Janssen announced new data from the Phase 3 study, IM-UNITI, showing that a significantly greater proportion of adult patients with moderate to severe Crohn's disease receiving maintenance treatment ...
Business Insider

New STELARA® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis

Final cumulative pooled IBD safety data support the longstanding safety profile of STELARA across all IBD approved indications Additional long term extension data demonstrate more than half of STELARA ...
Business Insider

Janssen Submits Application To U.S. FDA Seeking Approval Of STELARA® (ustekinumab) For Treatment Of Moderately To Severely Active Ulcerative Colitis

HORSHAM, Pa., Dec. 20, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S.
The Financial

Phase 3 Data Show STELARA Induced Clinical Response And Remission In The Treatment Of Patients With Moderate To Severe Crohn’s Disease

The FINANCIAL — Phase 3 data presented for the first time showed treatment with STELARA (ustekinumab) induced clinical response and clinical remission in patients with moderate to severe Crohn’s ...